Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.

Seminars in immunology - 1 Feb 2020

Gautam Shailendra K, Kumar Sushil, Dam Vi, Ghersi Dario, Jain Maneesh, Batra Surinder K

Abstract excerpt

Pancreatic cancer (PC) is a highly lethal malignancy with a dismal five-year survival rate. This is due to its asymptomatic nature, lack of reliable biomarkers, poor resectability, early metastasis, and high recurrence rate. Limited efficacies of current treatment modalities treatment-associated toxicity underscore the need for the development of immunotherapy-based approaches. For non-resectable, locally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes

Share to Immunotherapy

Share to Mutation

Share to Pancreatic Neoplasms

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 31952903
DOI: 10.1016/j.smim.2020.101391
PMCID: PMC7160012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.PMID 31952903Read ↗

Integrative Analysis of MUC4 to Prognosis and Immune Infiltration in Pan-Cancer: Friend or Foe?Semantic proximity Read ↗

B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDACSemantic proximity Read ↗

A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard TreatmentSemantic proximity Read ↗

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read ↗

Comprehensive Analysis of Clinical Prognosis and Molecular Immune Characterization of TPM4 in Pancreatic CancerSemantic proximity Read ↗

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.Semantic proximity Read ↗

Unraveling the glyco-immunity nexus in pancreatic cancerSemantic proximity Read ↗

Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancySemantic proximity Read ↗

Muc1 ImmunotherapySemantic proximity Read ↗

Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancerSemantic proximity Read ↗

Human MUC4 mucin cDNA and its variants in pancreatic carcinoma.Semantic proximity Read ↗

The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.